Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
OBIO vs BHST: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
OBIO Captures Overall Composite Edge (41.1 SELL vs 58.2 HOLD), While BHST Leads 5–1 on Growth & Valuation Pillars
OBIO Overall Winner
6-Pillar Tally: OBIO 1 – 5 BHST
Matrix Metrics: OBIO 2 – 6 BHST
As of Nov 20, 2026, Orchestra BioMed Holdings, Inc. (OBIO) captures the overall head-to-head institutional edge over BioHarvest Sciences Inc. (BHST) on higher Unified Composite conviction (41.1/100 SELL vs. 58.2/100 HOLD) after splitting the core matrix 2–6 (led by Options & Positioning), while BHST wins 5–1 across the 6-pillar growth and valuation breakdown. OBIO trades at $6.58 (N/M Forward P/E, -195.4% operating margin) versus BHST at $1.30 (N/M Forward P/E, -18.0% operating margin).
- Composite vs. Pillar Nuance: While BHST currently prints a higher short-term Unified Composite Score (58.2/100 HOLD vs. OBIO 41.1/100 SELL), OBIO captures the overall institutional head-to-head verdict (2–6 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (-195.4% vs. -18.0% operating margin) and revenue trajectory (-89.4% vs. +3.8% YoY).
- Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.9); meanwhile BHST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About OBIO vs BHST
OBIO
Head-to-Head Winner
Orchestra BioMed Holdings, Inc. Ordinary Shares
$6.58
-6.0% 1D
Market Cap
$550.9M
TTM Revenue
$31M
Forward P/E
N/M
Beta / 30D Vol
1.18β · 88% Vol
Unified Composite Score
41.1
SELL
Tech 15.0
Fund 36.0
Flow 64.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
BHST
BioHarvest Sciences Inc. Common Stock
$1.30
-1.52% 1D
Market Cap
$29.9M
TTM Revenue
$35M
Forward P/E
N/M
Beta / 30D Vol
0.25β · 86% Vol
Unified Composite Score
58.2
HOLD
Tech 75.0
Fund 57.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (OBIO 1 – 5 BHST)
1. Valuation Multiples
BHST
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
17.9x
0.7x
2. Growth & Scale
BHST
Revenue Growth (YoY)
-89.4%
+3.8%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$31M
$35M
Market Cap
$550.9M
$29.9M
3. Profitability & Quality
BHST
Gross Margin
99.6%
59.0%
Operating Margin
-195.4%
-18.0%
Net Profit Margin
-182.5%
-31.2%
Return on Equity (ROE)
-182.3%
-142.5%
4. Balance Sheet & Cash Flow
BHST
Cash Generation (TTM)
-$64M
-$9.4M
Cash Flow Margin
N/A
-26.6%
Net Cash / Leverage
$9.0M Net Debt (4.72x D/E)
$5.1M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
OBIO
Options Structure Phase
CONSOLIDATION
UNCLASSIFIED
Current IV / %ile
78.2% (21st %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
ACCUMULATION · Markup
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
BHST
OpEx & R&D Intensity
N/A
77.0% of Rev ($27M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Packaged Foods Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: OBIO (2) vs BHST (6)| Institutional Metric | OBIO | BHST | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $550.9M | $29.9M | OBIO | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -89.4% | +3.8% | BHST | |
| Operating Margin (TTM) | -195.4% | -18.0% | BHST | |
| Net Profit Margin | -182.5% | -31.2% | BHST | |
| Return on Equity (ROE) | -182.3% | -142.5% | BHST | |
| 52-Week Range Position | 72% ($3–$8) | 6% ($1–$7) | OBIO | |
| Beta / 30D Volatility | 1.18β · 88% Vol | 0.25β · 86% Vol | BHST | |
| Unified Institutional Score | 41.1 / 100 (SELL) | 58.2 / 100 (HOLD) | BHST | |
| Trailing 12M Revenue (USD) | $31M | $35M | Scale | |
| Gross Profit Margin (TTM) | 99.6% | 59.0% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 17.9x EV/Rev | N/M PEG · 0.7x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$64M ($9.0M Net Debt (4.72x D/E)) | -$9.4M ($5.1M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
OBIO +42.91 pp
3M Horizon
OBIO +57.55 pp
6M Horizon
OBIO +128.39 pp
1Y Horizon
OBIO +120.6 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OBIO Revenue | BHST Revenue | OBIO Op. Margin | BHST Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2022 | $0M | N/A | -924.3% | N/A | OBIO |
| FY2023 | $0M | $10M | -1866.2% | -78.6% | BHST |
| FY2024 | $0M | $30M | -2437.5% | -27.7% | BHST |
| FY2025 | $30M | $30M | -154.7% | -16.2% | BHST |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
OBIO
CONSOLIDATION
Current IV
78.2%
IV Percentile
21st %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
BHST
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact BHST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
OBIO Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
BHST Moat Profile
Cyclical / Execution-Driven Positioning
Packaged Foods Operator
OpEx & R&D Reinvestment
77.0% of Rev ($27M)
90D Engineering Disclosures
0 Published
Investor FAQ OBIO vs BHST Key Questions & Quantitative Answers
As of Nov 20, 2026, Orchestra BioMed Holdings, Inc. (OBIO) captures the overall head-to-head institutional edge over BioHarvest Sciences Inc. (BHST) on higher Unified Composite conviction (41.1/100 SELL vs. 58.2/100 HOLD) after splitting the core matrix 2–6 (led by Options & Positioning), while BHST wins 5–1 across the 6-pillar growth and valuation breakdown. OBIO trades at $6.58 (N/M Forward P/E, -195.4% operating margin) versus BHST at $1.30 (N/M Forward P/E, -18.0% operating margin). Composite vs. Pillar Nuance: While BHST currently prints a higher short-term Unified Composite Score (58.2/100 HOLD vs. OBIO 41.1/100 SELL), OBIO captures the overall institutional head-to-head verdict (2–6 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (-195.4% vs. -18.0% operating margin) and revenue trajectory (-89.4% vs. +3.8% YoY). Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.9); meanwhile BHST is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BHST leads the Growth & Scale pillar: OBIO posts -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin), compared with BHST at +3.8% YoY revenue growth and +0.0% YoY earnings growth on $35M TTM revenue (59.0% gross margin, -18.0% operating margin). Across the 4-period historical trajectory (FY2022 to FY2025), OBIO cumulative revenue shifted N/A while BHST shifted +200.0%. In operating R&D and SG&A reinvestment, OBIO deploys N/A (0 90-day corporate R&D disclosures) versus 77.0% of Rev ($27M) (0 disclosures) for BHST.
BHST screens cheaper on headline valuation multiples. OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.9x EV/Revenue (unreported FCF margin), whereas BHST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.7x EV/Revenue (-26.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OBIO (-182.3% ROE) versus BHST (-142.5% ROE) capital efficiency.
In options market volatility and institutional positioning, OBIO carries 78.2% implied volatility (21st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.18β · 88% Vol realized risk). By comparison, BHST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.25β · 86% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
BHST vs OBIO · Reverse Pair
OBIO vs OABI
· Sector Peer
BHST vs ACOG
· Sector Peer
BHST vs ELVA
· Sector Peer
BHST vs KGEI
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma